Atossa Therapeutics, Inc.
ATOS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001488039
No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Atossa Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 52 | 54 | +2 |
| Shares | 16.0M | 16.2M | +166.7K (+1.0%) |
| Value | $20.2M | $11.9M | −$8.26M (−40.9%) |
New holders (8)
Institutions that held Atossa Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Connor, Clark & Lunn Investment Management Ltd. | 133,591 | $98.4K | 0.00% |
| Citadel Advisors LLC | 45,156 | $33.3K | 0.00% |
| UBS Group AG | 33,359 | $24.6K | 0.00% |
| HRT Financial LP | 29,138 | $21.0K | 0.00% |
| Raymond James Financial Services Advisors, Inc. | 12,025 | $8.86K | 0.00% |
| Atria Wealth Solutions, Inc. | 10,000 | $7.37K | 0.00% |
| Qube Research & Technologies Ltd | 54 | $40 | 0.00% |
| NBC Securities, Inc. | 150 | $0 | 0.00% |
Sold out (6)
Institutions that held Atossa Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| D. E. Shaw & Co., Inc. | 216,528 | $272.8K |
| Wolverine Trading, LLC | 18,734 | $24.0K |
| Cetera Advisor Networks LLC | 13,332 | $16.8K |
| Dark Forest Capital Management LP | 10,193 | $12.8K |
| Baader Bank INC | 10,861 | $10.6K |
| Citigroup Inc | 170 | $214 |